Frazier Life Sciences Management, L.P. Arcutis Biotherapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.7 Billion
- Q2 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 8,785,284 shares of ARQT stock, worth $80.5 Million. This represents 4.82% of its overall portfolio holdings.
Number of Shares
8,785,284
Previous 8,785,284
-0.0%
Holding current value
$80.5 Million
Previous $87.1 Million
6.16%
% of portfolio
4.82%
Previous 4.57%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
193Shares Held
127MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.6MShares$106 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$91.6 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$89.9 Million2.7% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$79 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X06.88MShares$63 Million0.39% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $551M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...